PNETs are classified as functional or non-functional, influencing symptoms and treatment strategies. Tumor grade impacts prognosis and treatment plans. Diagnosis involves imaging, blood tests, and ...
Cabometyx is now approved for advanced pancreatic and extra-pancreatic NETs, offering a new treatment option for these patients. The phase 3 CABINET trial showed Cabometyx significantly improved ...
The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...
In the closing segment, Dr Shaheen reflects on unmet needs and future directions for patients with advanced pancreatic neuroendocrine tumors. She acknowledges that while treatment options have ...
Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS of ...
Exelixis Inc. (NASDAQ:EXEL) is one of the most undervalued quality stocks to buy according to hedge funds. On July 24, Exelixis announced that its partner Ipsen received approval from the European ...
For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer.
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further exploratory and post-hoc subgroup analysis data focusing on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results